Brigatinib (Alunbrig)

SELF ADMINISTRATION - ORAL

Indications for Prior Authorization:

  • Treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib

Patients must meet the following criteria for the indication(s) above:

  • Prescribed by an oncologist, AND
  • The patient has metastatic NSCLC that is anaplatic lymphoma kinase (ALK)-positive, AND
  • The patient has tried and failed Xalkori and Zykadia

Dosing:

  • 90 mg orally once daily for the first 7 days;
  • if 90 mg is tolerated during the first 7 days, increase the dose to 180 mg orally once daily
  • If treatment with Alunbrig is interrupted for 14 days or longer for reasons other than adverse reactions, resume treatment at 90 mg once daily for 7 days before increasing to the previously tolerated dose

Approval:

  • 1 year

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.

Press Esc to cancel

El sitio Web al que está siendo transferido no es provisto por WHA. Las Condiciones de Uso y las Prácticas de Privacidad en Internet de WHA no se aplican a este sitio Web asociado que usted está usando. Revise las políticas sobre la privacidad y condiciones de uso de este sitio Web asociado. WHA no tiene control sobre la exactitud, la totalidad o la actualidad del contenido del sitio Web asociado. WHA no puede garantizar que los servicios de traducción de idiomas estarán disponibles en el sitio vinculado.

Presione «Esc» para cancelar